ArticleJournal of translational medicine2026
Guanylate-binding protein 2 (GBP2) drives pancreatic cancer cell proliferation by promoting cell cycle progression via the SP1/SKP2/P27 axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Huwang Mingmu decoction protects retinal neurons in early diabetic retinopathy by suppressing the IL-1β-c-Jun-GS pathway: an in vivo and in vitro study.In vitro cellular & developmental biology. Animal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGuanylate-binding protein 2 (GBP2) has been reported to be involved in the progression of various human malignancies, but its specific functions and underlying molecular mechanisms in pancreatic cancer remain poorly understood.
methodsThe expression level of GBP2 in pancreatic cancer tissues and cell lines was detected, and the correlation between GBP2 expression and clinicopathological features as well as patient prognosis was analyzed. In vitro and in vivo experiments were performed to investigate the effect of GBP2 on pancreatic cancer cell proliferation and cell cycle progression. RNA-sequencing was conducted to screen downstream regulatory targets of GBP2, and molecular mechanism assays (including ubiquitination assay, co-immunoprecipitation) were carried out to verify the regulatory relationship between GBP2, SP1, TRIM25 and SKP2.
resultsGBP2 was significantly upregulated in pancreatic cancer tissues and cell lines, and high GBP2 expression was closely associated with a poor prognosis, an advanced TNM stage and a higher tumor grade. Functional experiments showed that GBP2 promotes pancreatic cancer cell proliferation by inducing cell cycle progression. Mechanistically, GBP2 competes with the E3 ubiquitin ligase TRIM25 for binding to transcription factor SP1, thereby inhibiting SP1 ubiquitination and proteasomal degradation. The stabilized SP1 further enhances its binding to the SKP2 promoter, upregulates SKP2 transcription, and activates the SKP2/p27 signaling axis to drive tumor progression.
conclusionsThis study reveals a novel GBP2-SP1-SKP2-p27 signaling pathway that promotes pancreatic cancer progression. GBP2 may serve as a potential therapeutic target for pancreatic cancer, which requires further validation through pharmacological studies and patient-derived organoid models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.